Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 67-75 , March 2007

Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission

  • Frederick R. Appelbaum (Director Clinical Research Division, FHCRC Head Division of Medical Oncology, UWMC)

      Affiliations

    • Corresponding Author InformationAddress: Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-310, PO Box 19024, Seattle, WA 98109-1024, USA. Tel.: +1 206 667 4412; Fax: +1 206 667 6936.

References 

  1. Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 1996;10:1874–1882
  2. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. British Journal of Haematology. 1998;102:1344–1353
  3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075–4083
  4. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. 2002;118:385–400
  5. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240
  6. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103:1652–1658
  7. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplantation. 2000;26:397–404
  8. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology. 2006;24:444–453
  9. Lazarus HM, Perez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: A retrospective analysis from the Center for International Blood and Marrow Transplant Research. British Journal of Haematology. 2006;132:755–769
  10. Ringden O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplantation. 1997;19:963–968
  11. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–2971
  12. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. The New England Journal of Medicine. 2004;351:2276–2285
  13. Krauter J, Heil G, Hoelzer D, et al. Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. Blood. 2005;106:172;(abstract)
  14. Meshinchi D, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;(prepublished online August 15, 2006)
  15. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011–4020
  16. Sorror ML, Maris MB, Storb RF, et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biology of Blood and Marrow Transplantation. 2005;11:23–24(abstract #67)
  17. Petersdorf E, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104:2976–2980
  18. Guo Z, Hood L, Malkki M, et al. Long-range multilocus haplotype phasing of the MHC. Proceedings of the National Academy of Sciences of the USA. 2006;103:6964–6969
  19. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of 131I-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237–1247
  20. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184–2191
  21. Pagel JM, Appelbaum FR, Sandmaier BM, et al. 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2005;106:119a;(abstract #397)

PII: S1521-6926(06)00076-4

doi: 10.1016/j.beha.2006.10.007

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 67-75 , March 2007

Article Tools

* Image Usage & Resolution